Dr. Gleave is a Distinguished Professor and Chairman of the Department of Urologic Sciences at UBC, and a British Columbia Leadership Chair. He is Co-Founder and Director of the Vancouver Prostate Centre, now a UBC and National Centre of Excellence. He is amongst the top cited and funded scientists in Canada, publishing > 600 papers with >60,000 citations, an H-Index of 122, and attracting >$120M in research funding. Dr. Gleave is a surgeon-scientist whose research characterizes molecular mechanisms mediating treatment resistance in cancer, and designing co-targeting strategies to improve cancer control. He patented several anti-cancer drugs and founded OncoGenex Pharmaceuticals to develop OGX-011 and OGX-427, inhibitors of cytoprotective chaperones clusterin and Hsp27 which progressed to Phase III and Phase II trials world-wide. OncoGenex was awarded Canadian Biotech Company of the Year in 2010. Dr. Gleave also recently co-founded Sitka and Sustained Therapeutics.

In 2017, Dr. Gleave was appointed to the Order of Canada for his leadership role in developing new treatments for prostate cancer and for his research on mechanisms mediating treatment resistance in cancer. In 2020, he was inducted as a Fellow in the National Academy of Inventors.

Dr Gleave is the recipient of numerous awards, including the 2018 Dr. Chew Wei Memorial Prize in Cancer Research, the Huggins Medal from the SUO in 2018, the Richard Williams Award from the AUA in 2017, the Barringer Medal from the American Association of GU Surgeons; the Eugene Fuller Award from the American Urological Association in 2013; the Aubrey Tingle Prize from the Michael Smith Foundation for Health Research; and the NCIC William Rawls Award for contributions to cancer control in Canada; He was appointed a Distinguished University Scholar at UBC in 2003 and awarded a BC Leadership Chair in 2005, the 2006 BC Biotech Award for Innovation and Achievement, and the 2007 BC Innovation Council Frontiers in Research Award.